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Abstract
PAX8 is a thyroid-specific transcription factor whose expression is dysregulated in thyroid
cancer. A recent study using a conditional knock-out mouse model identified 58 putative
PAX8 target genes. In the present study, we evaluated the expression of 11 of these genes
in normal and tumoral thyroid tissues from patients with papillary thyroid cancer (PTC).
ATP1B1,GPC3, KCNIP3, and PRLR transcript levels in tumor tissues were significantly
lower in PTCs than in NT, whereas LCN2, LGALS1 and SCD1 expression was upregulated
in PTC compared with NT. Principal component analysis of the expression of the most
markedly dysregulated PAX8 target genes was able to discriminate between PTC and NT.
Immunohistochemistry was used to assess levels of proteins encoded by the two most dyr-
egulated PAX8 target genes, LCN2 and GPC3. Interestingly, GPC3 was detectable in all of
the NT samples but none of the PTC samples. Collectively, these findings point to signifi-
cant PTC-associated dysregulation of several PAX8 target genes, supporting the notion
that PAX8-regulated molecular cascades play important roles during thyroid tumorigenesis.
Introduction
Tissue-specific transcription factors are critical for the development and function of the thyroid
gland. Several thyroid-specific transcription factors have been identified, including TTF-1
(NKX2-1), TTF-2 (FOXE1), PAX8, and HEX, and numerous roles have been described for
each [1]. PAX8 is a member of the PAX protein family [2] and interacts with specific DNA
sequences via its paired domain [3]. Its critical contribution during thyroid development was
first highlighted by Mansouri and coworkers, who demonstrated the absence of thyroid follicu-
lar cell formation in Pax8 knock-out mice [4]. Consistently, most cases of human congenital
hypothyroidism due to thyroid dysgenesis are caused by heterozygous loss-of-function muta-
tions involving PAX8 [5]. PAX8 also appears to control the expression of various genes that
play key roles in the function of thyroid follicular cells, including those encoding thyroglobulin
(TG), thyroperoxidase (TPO), and the sodium-iodide symporter (NIS, also known as solute
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carrier family 5, member 5, SLC5A5) [1,6,7]. A recent report by Marotta et al. confirms that
Pax8 is also essential for post-natal thyroid function. Mice subjected to conditional Pax8
knock-out exhibited undetectable serum levels of T4 and significantly increased levels of TSH.
Moreover, the thyroid glands of these animals were characterized by the absence of follicular
structure and dedifferentiation of the follicular cells, and they were significantly smaller than
those of control animals. The authors identified a set of 58 genes whose expression was dysre-
gulated after Pax8 knock-out and suggested that they might be used to delineate the molecular
cascades underlying PAX8’s regulation of thyroid follicular cell function [8].
Extensive work has been done to characterize PAX8’s role in thyroid carcinomas [6,9–12].
The general notion emerging from these studies is that PAX8 expression is frequently downre-
gulated in thyroid carcinoma and that this decrease may correlate with the dedifferentiation of
thyroid follicular cells, reflected by the loss or downregulated expression of genes involved in
the cells’ ability to concentrate iodine [10], thereby contributing to tumor aggressiveness [11].
In addition, the PAX8–PPARγ fusion gene has been found in roughly one-third of all follicular
thyroid carcinomas and a small fraction of follicular-variant papillary thyroid carcinomas
(PTCs) as well, but it is not present in classical PTCs [12].
To gain further insight into the roles played by PAX8 target genes during thyroid tumori-
genesis, we investigated their expression in a cohort of PTCs with well characterized clinicobio-
logical features.
Materials and Methods
The study was conducted with the approval of the Bioethics Committees of both participating
centers (Sapienza University of Rome, Policlinico Umberto I and the University of Udine,
Santa Maria della Misericordia Hospital). All tissue donors provided written informed consent
to the collection and analysis of tissue samples and clinical data and to the publication of the
results of the study. Unless otherwise stated, all commercial products mentioned below were
used in accordance with the manufacturers’ instructions.
Patient and samples
PAX8mRNA levels were assessed in surgical specimens of 36 PTCs collected between 2008
and 2014 at the University of Rome. All have been analyzed in previous reports [13,14].
Thirty-one of the tumors were classical-type (CT-PTCs) and the remaining five were follicu-
lar-variants (FV-PTCs). Specimens of normal thyroid tissue from the tumor-free lobe were
also tested for 18 of the 36 PTCs (15 CT-PTCs, 3 FV-PTCs). All tissues were immediately
snap-frozen and stored in liquid nitrogen prior to use. A single experienced pathologist
reviewed all tissues to confirm the diagnosis of PTC and select samples suitable for use in the
study (i.e., tumor tissue samples with a percentage of tumor cells exceeding 60%, normal tissues
exhibiting no signs of hyperplasia or thyroiditis). Each case was staged using the AJCC/UICC
TNM classification [15] and risk-stratified on the basis of the clinical and histological criteria
recommended by current American Thyroid Association (ATA) guidelines [16].
For immunohistochemistry studies, we used an archival series of 38 PTCs (all CT-PTCs)
and 12 NTs from the the University of Udine. The most representative block of each lesion was
retrieved from the archive and used for our analyses.
Evaluation of mRNA levels for thyroid-specific genes and PAX8 target
genes
Total RNA was isolated from tissue samples using Trizol reagent (Thermo Fisher Scientific,
Waltham, MA, USA), and first-strand cDNA was synthesized with the High Capacity cDNA
PAX8 Target Genes in PTC
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Reverse Transcription kit (Thermo Fisher Scientific). Gene expression profiling of thyroid tis-
sues was done by real-time PCR with custom Taqman Low Density Arrays (TLDA, Thermo
Fisher Scientific), each configured with predesigned assays (TaqMan Gene Expression Assays,
Life Technologies) for six thyroid-specific genes (SLC5A5, TPO, TG, TSHR, TTF1, PAX8) and
11 of the 58 putative PAX8-target genes identified by Marotta et al. on the basis of their studies
in PAX-8 knock-out mice, namely: FSTL1, LCN2, CA3, KCNIP3, PRLR, NFKBIA, GPC3, LUM,
LGALS1, SCD1, ATP1B1. The latter 11 genes were selected on the basis of the degree of dyregu-
lation they displayed in the mouse studies and their established roles in thyroid cell function or
in thyroid cancerogenesis [8]. Four housekeeping genes (glyceraldehyde-3-phosphate dehydro-
genase; beta-actin; hypoxanthine phosphoribosyltransferase 1, and beta-2 microglobulin) were
included in each reaction and tested as endogenous controls. The TaqMan arrays were pro-
cessed and analyzed on a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific), as
previously described [17]. The relative expression of each transcript was determined by the
comparative 2-ΔΔCt method using RQManager 1.2.1 software (Thermo Fisher Scientific).
Beta-actin was chosen as the endogenous control because of the stability of its expression levels
among samples. Final results were expressed as means ± standard deviation.
Detection of the BRAFV600Emutation
We analyzed cDNA from tumor tissues for the presence of the BRAFV600Emutation. The PCR
reaction was performed on 100 ng of cDNA using 200 mM dNTPs, 10 pmol of specific primers
for exon 15 of BRAF (Fw: 50-CACAGAGACCTCAAGAGTAA-30, Rv: 50-ATGACTTCTGGT
GCCATCCA-30), 1.5 mMMgCl2, 1 U of AmpliTaq Gold, and Buffer 1x AmpliTaq Gold DNA
Polymerase (Thermo Fisher Scientific). The cycling conditions for PCR program included
10 min at 95°C, followed by 35 cycles (each consisting of 30 sec at 95°C, 30 sec at 58°C, and
30 sec at 72°C), and a final 7 min extension at 72°C.
All PCR products were purified with the NucleoSpin Gel and PCR Clean-up Kit (Macherey-
Nagel GmbH & Co. KG, Düren, Germany), and sequenced using one of the primers described
above and the Big DyeTM Terminator v. 3.1 Cycle Sequencing Kit (Thermo Fisher Scientific).
The products of the sequencing reaction were purified with NucleoSeq Columns (Macherey-
Nagel GmbH & Co. KG) and analyzed with an Applied Biosystems 3130 XL Automated
Sequencer (Thermo Fisher Scientific). This protocol has been shown to detect mutations with
allelic frequencies as low as 10% [18].
To confirm the presence of a BRAFV600Emutation, we repeated PCR and sequencing reac-
tions at least twice.
Collection of TCGA public data
Gene expression data on 486 PTCs and 59 normal thyroid tissues were downloaded from
http://gdac.broadinstitute.org/(gdac.broadinstitute.org_THCA.Merge_rnaseqv2__
illuminahiseq_rnaseqv2__unc_edu__Level_3__RSEM_genes_normalized__data.Level_3.
2015060100.0.0.tar). Matching clinical data were downloaded from http://www.cbioportal.org/
(Papillary Thyroid Carcinoma (TCGA, Cell 2014).csv). RNA-Seq data were expressed as RNA-
seq by Expectation Maximization (RSEM) values [19].
Immunohistochemistry
Antibodies against PAX8, LCN2, and GPC3 were purchased from Abcam (Cambridge, UK),
Sigma Aldrich (St. Louis, MO, USA) and Aczonpharma (Bologna, Italy), respectively. Forma-
lin-fixed paraffin-embedded tissue sections (5 μm) mounted on SuperFrost Plus slides (Men-
zel-Gläser, Braunschweig, Germany) were placed in the PT Link Pre-Treatment module
PAX8 Target Genes in PTC
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(DAKO A/S, Glostrup, Denmark), which automatically performs the entire pre-treatment pro-
cess, including deparaffinization, rehydration, and epitope retrieval, the latter done with
DAKO’s Low pH Target Retrieval Solution (0.001 M citrate buffer pH 6.0) at 98°C for 40 min.
Endogenous peroxidase activity was blocked by a 5-min incubation in the Peroxidase Block
solution (DAKO). Primary antibodies (dilutions: 1:30 for PAX8, 1:500 for LCN2, 1:50 for
GPC3) were applied and sections incubated for 60 minutes at room temperature. After wash-
ing, slides were incubated in the DAKO EnVision FLEX System (DAKO) and the reaction visu-
alized using 3–3 diaminobenzidine tetrahydrochloride as the chromogen. The sections were
counterstained with Mayer hematoxylin. Appropriate positive and negative tissue controls
were run for each antibody. Brown-colored cells were identified as positive.
PAX8 staining intensity was semiquantitatively rated using the H-score method [20]. The H
score for each sample was determined independently by two experienced pathologists, and the
average used for all analyses.
Statistical Analysis
Analysis of differential expression between groups was based on the Mann–Whitney test.
When more than two groups were compared, we used the Kruskal–Wallis test with the post
hoc Dunn’s multiple comparison test. Correlation analysis was performed with the Spearman’s
rho rank correlation coefficient. GraphPad Prism version 5.0 statistical software was employed
for all the above analyses. P-values< 0.05 were considered statistically significant. Bonferroni
correction for multiple comparisons was used to evaluate adjusted p values (adj p-value). Prin-
cipal component analysis (PCA) was carried out with the prcomp function from the built-in
stats package in R software v.3.1.1, which uses the singular value decomposition (SVD).
Receiver-operating characteristic (ROC) curves and areas under the ROC curve (AUC) were
analyzed with the pROC package on R software, v.3.1.1, as previously reported [21,22], using
the Youden Index and the DeLong method.
Results
PAX8 expression in Normal Thyroid and PTC
Analysis of mean PAX8mRNA levels in the 36 PTCs and 18 normal thyroid tissue (NT) sam-
ples revealed significantly reduced expression in the tumors (Fig 1A). A similar picture
emerged when PAX8 protein levels in the second (archival) cohort of PTC and NT samples
were assessed by immunohistochemistry: all 12 NT samples showed strong PAX8 positivity,
whereas PTCs were either moderately (21 samples) or weakly (17 samples) positive (Fig 1B
and 1D). The mean H score for the NT group was significantly higher than that of the PTCs
(Fig 1E).
PAX8 gene expression in the PTCs displayed strong correlation with TG, TSHR, and TTF1
expression and weak correlation with expression of the iodine transporter gene SLC5A5. No
correlation was observed between PAX8 and TPOmRNA levels. (S1 Fig).
mRNA levels of PAX8 target genes in NT and PTC
As shown in Table 1, the 11 putative PAX8-target genes investigated in the present study
included four (ATP1B1, GPC3, KCNIP3, and PRLR) with significantly lower mRNA levels in
PTCs than in NTs and three (LCN2, LGALS1, and SCD1) that displayed significantly upregu-
lated expression in the tumors, as compared with NT. The dysregulation of GPC3, KCNIP3,
LCN2, LGALS1, and SCD1 remained significant after correction for multiple testing (Bonfer-
roni-adjusted P values< 0.05). These five genes displayed directionally similar dysregulations
PAX8 Target Genes in PTC
PLOSONE | DOI:10.1371/journal.pone.0156658 June 1, 2016 4 / 15
Fig 1. PAX8 expression in normal and tumor thyroid tissues of PTC patients. (A) Mean (SD) PAX8mRNA levels
found in normal thyroid tissuesamples (n = 18) and PTCs (n = 36), assessed by qPCR. (B-D) Representative images of
immunohistochemical staining for PAX8 protein levels in (B) normal thyroid tissues; (C) PAX8-positive PTCs; and (D)
PAX8 Target Genes in PTC
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in PTCs from The Cancer Genome Atlas (TCGA) dataset, which were highly significant (p val-
ues ranging from 1.82x10-12 for SCD1 to 6.04x10-22 for LCN2) (data not shown).
Notably, FSTL1, LCN2, LGALS1, and SCD1 showed significantly higher mRNA levels in
CT-PTC than in FV-PTC. Compared with NTs, FV-PTCs displayed downregulated expression
of FSTL1 and GPC3, and CT-PTCs exhibited significant dysregulation (up or down) of GPC3,
KCNIP3, LCN2, LGALS1, PRLR, and SCD1 (S1 Table).
Interestingly, for six of the 11 putative PAX8 target genes, the dysregulation we observed in
PTCs (vs. NT) was directionally consistent with that reported in the thyroids of PAX8 knock-
out mice (Table 1). These included three of the genes displaying PTC-related downregulation
(ATP1B1, KCNIP3, and PRLR) and three of those that were upregulated in the tumors (LCN2,
LGALS1, SCD1). The genes whose expression showed the strongest correlation with PAX8
mRNA levels in the PTC group were ATP1B1 and KCNIP3 (Fig 2).
NFKBIA expression was also strongly correlated with PAX8mRNA levels in the PTCs (S2
Table). However, mRNA levels for this gene in NTs and PTCs were not significantly different
(Table 1). As for GPC3, its downregulation in PTCs vs. NT (Table 1) contrasts with the upregu-
lation reported in PAX-8 knock-out mice. Collectively, these data indicate that in PTCs,
PAX8-dependent regulation is conserved for only some of the target genes of this transcription
factor.
None of the 11 genes exhibited significantly different expression levels in PTCs with
(n = 21) vs. without (n = 15) the BRAFV600Emutation or in PTCs belonging to low (n = 17) vs.
intermediate (n = 19) risk groups (Table 2).
To determine whether the lack of significant differences in the last two analyses was due to
the low number of PTCs in each subgroup (i.e. BRAF-wt, BRAFV600E, low risk, and
PAX8-negative PTCs. (E) Mean H scores for immunohistochemical labeling of PAX8 protein in normal thyroid tissues
(12 samples) and PTC (38 samples).
doi:10.1371/journal.pone.0156658.g001
Table 1. Expression of putative PAX8 target genes in the 36 PTCs.
Gene NT(n = 18) PTC(n = 36) p-value adjp-value
Upregulated genes in Pax8 knock-out mice*
CA3 1±0.462 1.273±0.721 ns ns
FSTL1 1±0.496 1.068±0.861 ns ns
GPC3 1±0.626 0.067±0.091 <0.0001 0.0011
LCN2 1±0.857 44.400±78.410 <0.0001 0.0011
LGALS1 1±0.643 2.793±2.941 0.0023 0.0253
LUM 1±0.743 2.596±8.738 ns ns
SCD1 1±0.948 3.158±2.682 <0.0001 0.0011
Downregulated genes in Pax8 knock-out mice*
ATP1B1 1±0.493 0.720±0.330 0.0318 ns
KCNIP3 1±0.829 0.355±0.368 <0.0001 0.0011
NFKBIA 1±0.429 1.100±1.268 ns ns
PRLR 1±0.820 0.411±0.302 0.0017 ns
mRNA levels are expressed as mean ± SD.
p values were obtained by Mann-Whitney test.
adj p-value: adjusted p-values were evaluated using the Bonferroni method.
NT, Normal Thyroid; PTC, Papillary Thyroid Carcinoma.
* Data from Marotta et al., 2014.
doi:10.1371/journal.pone.0156658.t001
PAX8 Target Genes in PTC
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Fig 2. Putative PAX8 target genes whosemRNA levels were most strongly correlated with those of PAX8 in PTCs
Levels of mRNA for ATP1B1 (A) and KCNIP3 (B) are plotted against PAX8 mRNA levels measured in 31 CT-PTCs (•) and 5
FV-PTCs (). R and p values were calculated with the Spearman rank correlation test.
doi:10.1371/journal.pone.0156658.g002
PAX8 Target Genes in PTC
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intermediate risk tumors), we assessed mRNA expression levels for the 11 PAX8 target genes
present in the TCGA dataset. This analysis showed that, compared with BRAF-wt PTCs, those
harboring the BRAFV600Emutation displayed significantly higher expression of FSTL1, LCN2,
LGALS1, LUM, and SCD1 and significantly lower expression of GPC3, KCNIP3, and NFKBIA.
With the exception ofGPC3, all of these genes continued to display significant differential expres-
sion in BRAF-wt and BRAFV600E PTCs after Bonferroni correction (S3 Table). Analysis of the
TCGA dataset also revealed significant differential expression in PTCs of FSTL1, KCNIP3, LCN2,
LGALS1, LUM, and SCD1 related to ATA risk statuses. After correction for multiple testing, the
most striking differences were observed for the LCN2 gene, which displayed higher expression in
intermediate- and high-risk PTCs compared with those considered low-risk (fold change 2.384,
adjusted p-value<0.001, and fold change = 2.568, adjusted p-value<0.001, respectively) (S2A
Fig, S4 Table). These findings prompted us to subject LCN2 to ROC analysis to assess its accuracy
in discriminating high risk-PTC from low risk-PTC. The diagnostic accuracy of this potential
marker was mediocre, however, with an AUC of 77.3% [95% CI of 68.64–85.88%], specificity of
62%, sensitivity of 83.3%, and accuracy of 64.7% (S2B Fig).
To determine whether dysregulation of PAX8 target genes can discriminate between NT
and PTCs, expression levels of the four most markedly dysregulated genes (LCN2, GPC3,
KCNIP3 and SCD1) in our dataset were subjected to principal component analysis (PCA). As
shown in Fig 3A, NT and PTC clearly occupy different positions within the PCA space. To vali-
date this finding, we repeated the PCA using expression levels of LCN2, GPC3, KCNIP3 and
SCD1 found in the TCGA dataset. Again, the positions of NT and PTC were distinct (Fig 3B).
Expression levels of the PAX8 target genes most markedly dysregulated in PTCs effectively dis-
criminates between these tumors and NT, suggesting similarity in dysregulatory mechanisms
among PTC.
Table 2. Expression of putative PAX8 target genes in the 36 PTCs stratified by ATA risk andBRAFmutational status.
Gene *ATA risk **BRAF status
Low Risk (n = 17) Intermediate Risk (n = 19) BRAF–wt (n = 21) BRAFV600E (n = 15)
Upregulated genes in Pax8 knock-out mice§
CA3 1±0.556 0.930±0.550 1±0.535 0.956±0.577
FSTL1 1±0.824 1.376±1.067 1±0.857 0.926±0.724
GPC3 1±1.236 0.719±1.092 1±1.178 0.653±1.011
LCN2 1±1.234 1.637±3.033 1±1.103 1.985±3.495
LGALS1 1±1.329 1.293±1.112 1±1.172 0.903±0.858
LUM 1±3.374 0.417±0.531 1±1.635 2.524±8.240
SCD1 1±0.904 0.772±0.573 1±1.057 1.707±1.246
Downregulated genes in Pax8 knock-out mice§
ATP1B1 1±0.447 0.870±0.412 1±0.440 1.065±0.509
KCNIP3 1±0.649 0.944±1.265 1±1.000 0.531±0.448
NFKBIA 1±1.307 0.805±0.736 1±1.125 0.580±0.602
PRLR 1±2.047 0.571±0.771 1±1.559 0.178±0.126
mRNA levels are expressed as mean ± SD.
* mRNA levels in the ATA risk intermediate group are expressed as relative quantity with respect to the ATA risk low group, arbitrarily considered as 1.0.
** mRNA levels in samples with the BRAFV600E mutation are expressed as relative quantity with respect to BRAF-wt group, arbitrarily considered as 1.0.
All mRNA values indicated in this table have p values >0.05 when compared to respective control groups, as assessed by Mann Whitney test.
wt, wild type.
§ Data from Marotta et al., 2014.
doi:10.1371/journal.pone.0156658.t002
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Immunohistochemical detection of LCN2 and GPC3
At the transcriptional level, LCN2 and GPC3 were the PAX8 target genes with the most
markedly altered expression in PTCs relative to NTs (upregulation expression for LCN2,
downregulation for GPC3). We therefore focused our subsequent efforts on these two genes:
immunohistochemistry was used to assess LCN2 and GPC3 protein levels in a different cohort
of tissues, which included 12 NT samples and 38 PTCs. Representative results are shown in Fig
4. LCN2 was undetectable in all of the NTs and 31 of the 38 PTCs. These results were not
completely surprising: in the Human Protein Atlas (http://www.proteinatlas.org/), negative
immunohistochemical findings for LCN2 protein expression are reported in normal and
cancerous thyroid tissues. LCN2 protein levels in most samples are probably below the detec-
tion limit of immunohistochemical techniques. Only in a few PTCs were mRNA levels
increased sufficiently to produce protein levels detectable by antibody staining. As for GPC3
protein, it was detectable in all NTs but in none of the PTC samples (Fig 4). Thus, GPC3 stain-
ing is a good candidate for discriminating between NT and PTC.
Fig 3. PCA of PAX8 target genes displaying marked PTC-related dysregulation. Analysis was
performed with data for the four PAX8 target genes (LCN2,GPC3, KCNIP3, SCD1) that were most markedly
dysregulated in PTCs (red diamonds) compared with normal thyroid (NT) tissues (green diamonds). (A) Our
dataset (36 PTC and 18 NTs). (B) TCGA dataset (486 PTC and 59 NTs). PCA was performed with the built-in
prcomp function in R software.
doi:10.1371/journal.pone.0156658.g003
PAX8 Target Genes in PTC
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Fig 4. Immunohistochemical detection of LCN2 and GPC3. (A) LCN2 staining in normal thyroid. (B) LCN2 staining in PTC. (C)
GPC3 staining in normal thyroid. (D) GPC3 staining in PTC. (E) Proportions of positive and negative samples in each tissue
group.
doi:10.1371/journal.pone.0156658.g004
PAX8 Target Genes in PTC
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Discussion
Several findings indicate that expression of the thyroid-specific transcription factor PAX8 is
reduced in thyroid cancer [23]. Thus, investigation of its targets could improve our under-
standing of the mechanisms of thyroid tumorigenesis. In addition to TG, TPO, and SLC5A5
genes [1,7,24], a large number of other putative Pax8 target genes have recentely been identi-
fied based in studies in mouse conditional knock-out model [8]. Here, we evaluated the expres-
sion in NT and PTC of 11 of these genes with established roles in thyroid cell function or in
cancerogenesis, which displayed marked dysregulation in the Pax8 knock-out mice [8]. Five of
the 11 genes (GPC3, KCNIP3, LCN2, LGALS1, and SCD1) presented significantly modified
expression in PTCs relative to NT (Mann-Whitney test with Bonferroni adjustment), and all
five displayed consistently dysregulated expression in the TCGA dataset, strenghtening the
hypothesis that a substantial proportion of PAX8 target genes are involved in PTC tumorigene-
sis. We then looked at the two genes displaying the most markedly upregulated and downregu-
lated expression in the tumors (LCN2 and GPC3, respectively). LCN2 encodes lipocalin 2 or
neutrophil gelatinase associated lipocalin (NGAL), a secreted 25-kDa protein that binds iron
[25] and is overexpressed in various epithelial cancers [26]. Several findings indicate that LCN2
overexpression is associated with tumor size, stage, and invasiveness [27], and it has been pro-
posed as a negative prognostic indicator in several types of cancer [28,29]. We found that
LCN2mRNA levels were markedly higher in PTCs than in NTs, and immunostaining for
LCN2 protein was positive in several tumors but in none of the NT samples. Ma and coworkers
recently showed that LCN2 is overexpressed in PTC relative to NT [30]. Moreover, LCN2
expression has been proposed as an efficient marker for differentiating benign from malignant
thyroid neoplasms [31]. Consistent with these findings, in vitro experiments have shown that
LCN2 is a survival factor for thyroid neoplastic cells and that its overexpression increases the
cells’ metastatic potential [32,33]. The mechanism by which LCN2 contributes to thyroid
tumorigenesis is not known, but studies involving other neoplasms suggest that it might be
related to the protein’s promotion of epithelial-mesenchymal transition and/or its ability to
sequester iron [25,26]. In our samples, however, LCN2mRNA levels were not significantly
related to ATA risk groups. This finding may be due to the limited number of intermediate-
risk cases and the absence of high-risk tumors in our cohort. Indeed, in the TCGA dataset,
mean LCN2mRNA values are significantly different in low risk groups, relative to high-risk as
well as to intermediate-risk groups (S2A Fig, S4 Table). In this analysis, only the mean LCN2
transcript levels were correlated with aggressiveness: single LCN2mRNA levels were not an
efficient indicator of ATA high risk (S2B Fig).
GPC3 encodes the glypican-3 protein, which is a membrane-bound heparan sulfate proteo-
glycan. The biological role of GPC3 is linked to the Hedgehog (Hh) signaling pathway [34]. In
fact, Hh signaling activity has been shown to be elevated in GPC3-null mice [35,36]. Moreover,
GPC3 binds with high affinity to both Sonic Hedgehog and Indian Hedgehog and competes
with Patched for Hh binding [35,36]. Conflicting data have been reported on the role of GPC3
in cancer. In fact, while this gene is overexpressed in liver cancer and germ-cell malignancies
[37], other studies indicate that it is silenced in breast and lung cancers, where it is thought to
play the role of a tumor suppressor [38,39]. The latter conclusion is consistent with recent find-
ings by Liu and coworkers, who showed that siRNA knock-down of GPC3 expression in ovar-
ian cancer cells induces increases in cell proliferation as well as in migration and invasion
properties [40]. Several studies indicate that aberrant Hh signaling plays a role in thyroid neo-
plasia [41,42], and GPC3 expression has also been investigated in thyroid cancer [43]. In sharp
contrast to our findings, immunohistochemistry studies by Yamanaka and coworkers indicate
that GPC3 is overexpressed in PTC. We do not have an explanation for this discrepancy.
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However, it is important to note that our immunohistochemical data are consistent with the
mRNA levels we observed in a different cohort of samples. Moreover, data in the Human Pro-
tein Atlas (http://www.proteinatlas.org/) also show that GPC3 protein expression is reduced in
PTC compared with NT, and, in a recent study of TCGA, GPC3mRNA levels were markedly
reduced in PTC compared with NT [44]. Collectively, these data indicate that GPC3 might
exert an oncosuppressor function that is lost during thyroid tumorigenesis. Our findings sug-
gest that assessment of GPC3 expression could be used to discriminate between PTC and NT.
In conclusion, our study provides evidence of significant dysregulation of several putative
PAX8 target genes in PTC, supporting the notion that PAX8-regulated molecular cascades
play important roles in thyroid tumorigenesis. The molecular mechanisms underlying this dys-
regulation are still unclear and should be addressed in future studies.
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